Get the Stockscreener App
4.514
3.32%
-0.156
Taysha Gene Therapies Inc stock is traded at $4.514, with a volume of 574.25K.
It is down -3.32% in the last 24 hours and down -4.34% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$4.67
Open:
$4.64
24h Volume:
574.25K
Relative Volume:
0.20
Market Cap:
$1.24B
Revenue:
$6.31M
Net Income/Loss:
$-99.93M
P/E Ratio:
-12.74
EPS:
-0.3544
Net Cash Flow:
$-85.14M
1W Performance:
-5.74%
1M Performance:
-4.34%
6M Performance:
+52.53%
1Y Performance:
+178.70%
1-Day Range:
$4.51
$4.67
1-Week Range:
$4.51
$5.07
52-Week Range:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.515 | 1.28B | 6.31M | -99.93M | -85.14M | -0.3544 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.75 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
757.41 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
768.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.73 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
319.27 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Raymond James | Strong Buy |
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
What is the next catalyst for Taysha Gene Therapies Inc.Long Setup & Precise Buy Zone Identification - mfd.ru
Will Taysha Gene Therapies Inc. benefit from AI trendsTrade Entry Summary & Detailed Earnings Play Alerts - mfd.ru
How liquid is Taysha Gene Therapies Inc. stock2025 Breakouts & Breakdowns & Technical Pattern Alert System - mfd.ru
RTW INVESTMENTS, LP Reduces Stake in Taysha Gene Therapies Inc - GuruFocus
CEO Moves: How cyclical is Taysha Gene Therapies Incs revenue stream2025 Winners & Losers & Community Verified Trade Alerts - baoquankhu1.vn
GSA Capital Partners LLP Increases Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (TSHA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Rate Cut: What is the next catalyst for Taysha Gene Therapies IncEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Commit To Buy Taysha Gene Therapies At $2.50, Earn 16.8% Annualized Using Options - Nasdaq
Portfolio Recap: How does NBBK perform in inflationary periodsJuly 2025 Chart Watch & Consistent Return Investment Signals - baoquankhu1.vn
Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Analyst Consensus Reveals 136.56% Potential Upside - DirectorsTalk Interviews
Does Taysha Gene Therapies Inc. have declining or rising EPSQuarterly Earnings Summary & Fast Entry Momentum Alerts - mfd.ru
Here’s what analysts are saying about Taysha Gene Therapies (TSHA) - MSN
Can Taysha Gene Therapies Inc. outperform under higher oil pricesGDP Growth & Weekly Return Optimization Plans - mfd.ru
Taysha Gene Therapies, Inc. $TSHA Holdings Trimmed by Tybourne Capital Management HK Ltd. - MarketBeat
Is Taysha Gene Therapies Inc undervalued by DCF analysisJuly 2025 Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Retail Trends: What is the next catalyst for Taysha Gene Therapies IncPortfolio Gains Summary & High Accuracy Buy Signal Tips - baoquankhu1.vn
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies (TSHA) Awards Restricted Stock Units to Ne - GuruFocus
Did Rett Trial Milestones Just Shift Taysha Gene Therapies' (TSHA) Gene Therapy Approval Path Narrative? - Yahoo Finance
Taysha Gene Therapies, Inc. (TSHA) gains Wells Fargo’s support on Rett syndrome program progress - MSN
Taysha’s REVEAL Trial Progress Puts Rett Gene Therapy And Valuation In Focus - Sahm
Cell And Gene Therapy Enters ‘Disciplined Growth Cycle’ As Commercial Momentum Builds - Citeline News & Insights
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress - Insider Monkey
Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress - Finviz
Institution Moves: Does Taysha Gene Therapies Inc have strong fundamentals2025 Retail Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Taysha Gene Therapies, Inc. $TSHA Shares Sold by SG Americas Securities LLC - MarketBeat
Activity Recap: How cyclical is Taysha Gene Therapies Incs revenue streamWeekly Stock Report & Precise Trade Entry Recommendations - baoquankhu1.vn
Pivotal Trial for Taysha's Rett Syndrome Gene Therapy TSHA-102 Doses First Patient - CGTLive®
Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans - NeurologyLive
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
10 Best Strong Buy Stocks to Invest In Under $5 - Insider Monkey
Here’s What Analysts Are Saying About Taysha Gene Therapies (TSHA) - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells $649,747.75 in Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) CEO Sells 41,312 Shares of Stock - MarketBeat
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 26,918 Shares of Stock - MarketBeat
Kamran Alam Sells 78,968 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Kamran Alam Sells 23,849 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.2%What's Next? - MarketBeat
Taysha Gene Therapies commences underwritten public offering - MSN
Dip Buying: How liquid is Taysha Gene Therapies Inc stock2025 Support & Resistance & Entry Point Strategy Guides - baoquankhu1.vn
Trading Recap: Can PBYI generate free cash flowJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
VIX Spike: Is Taysha Gene Therapies Inc stock good for income investors2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells 200,000 Shares of Stock - MarketBeat
Nagendran sells Taysha gene therapies (TSHA) stock for $942k By Investing.com - Investing.com Canada
Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects - Insider Monkey
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
Buybacks Report: What is KIDSs TAM Total Addressable MarketIPO Watch & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.3%Should You Sell? - MarketBeat
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):